Literature DB >> 17827948

Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues.

Rosario Cuomo1, Maria Flavia Savarese, Rosalba Gargano.   

Abstract

Several reports have described post-infectious irritable bowel syndrome (Pi-IBS), while many animal and human studies have shown the presence of increased infiltration of inflammatory cells and hyperplasia of enterochromaffin cells in the intestinal mucosa after acute gastroenteritis. The potential value of probiotic bacteria in restoring normal gut function has been demonstrated by animal models of Pi-IBS. In humans, Pi-IBS can be prevented utilizing probiotics to reduce the duration of acute gastroenteritis, despite the variable efficacy shown in randomized control trials evaluating unspecified IBS. Here, advances in the pathophysiology supporting the post-infectious hypothesis are considered. In addition, the current role of probiotics in the management of Pi-IBS is discussed. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2007        PMID: 17827948     DOI: 10.1159/000103893

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  3 in total

Review 1.  Post-Infectious Irritable Bowel Syndrome.

Authors:  Yeong Yeh Lee; Chandramouli Annamalai; Satish S C Rao
Journal:  Curr Gastroenterol Rep       Date:  2017-09-25

2.  Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders?

Authors:  Shunji Ishihara; Monowar Aziz; Naoki Oshima; Yoshiyuki Mishima; Hiroshi Imaoka; Ichiro Moriyama; Yoshikazu Kinoshita
Journal:  Clin J Gastroenterol       Date:  2009-01-06

3.  Gastrointestinal symptoms and healthcare utilization have increased among patients with functional gastrointestinal and motility disorders during the COVID-19 pandemic.

Authors:  John Gubatan; Thomas Zikos; Estelle Spear Bishop; John Wu; Andrés Gottfried; Laren Becker; Aida Habtezion; Leila Neshatian
Journal:  Neurogastroenterol Motil       Date:  2021-08-11       Impact factor: 3.960

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.